Corindus Announces First Robotic-Assisted Interventions in Japan for CorPath GRX Post-Market Study
April 15 2019 - 6:45AM
Business Wire
Japan represents one of the largest markets for
PCI globally, with over 1,200 hospitals performing nearly 250,000
PCI procedures annually
Corindus Vascular Robotics, Inc. (“Corindus” or
the “Company”) (NYSE American: CVRS), a leading developer of
precision vascular robotics, announced today that the first
clinical robotic-assisted PCI procedures in Japan were completed in
partnership with Takafumi Ueno, MD, PhD, Director of Interventional
Cardiology, Center of Cardiovascular Disease, Kurume University
Hospital. These procedures mark initial enrollment in a post-market
study of CorPath GRX in Japan. CorPath GRX received Pharmaceutical
and Medical Device Agency (PMDA) approval in 2018 and A1 technical
fee reimbursement for Japan in March of this year.
“The acceptance of robotic-assisted PCI in Japan is an important
next step for Corindus to bring this critical medical advancement
to additional markets across the globe. Japan represents one of the
largest markets for PCI globally, with over 1,200 hospitals
performing nearly 250,000 PCI procedures annually,” said Mark
Toland, President and Chief Executive Officer of Corindus Vascular
Robotics. “We are thrilled to have partnered with Dr. Ueno, Kurume
University Hospital, and Japan Medicalnext to launch the first
vascular robotic program in Japan, offering these patients the
benefits of robotic-assisted PCI.”
This is the first CorPath GRX System placed by the Company’s
Japanese distribution partner, Japan Medicalnext Co., Ltd., a
wholly-owned entity of MC Healthcare, Inc. (a subsidiary of
Mitsubishi Corporation), following the launch of a partnership in
2017.
“After completing the first cases with CorPath GRX, I am
impressed with the capabilities of the system, including the level
of precision and control during complex procedures,” stated Dr.
Ueno. “Robotics will provide Japan with cutting-edge technology in
interventional medicine, and we are pleased to be one of the first
facilities in the Asia-Pacific region to offer this treatment to
our patients,” Dr. Ueno added.
To learn more about Corindus and CorPath GRX, please visit
www.corindus.com.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath®
platform is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. CorPath
GRX is the second generation robotic-assisted technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities
and range of procedures that can be performed robotically. We are
focused on developing innovative robotic solutions to revolutionize
treatment of emergent conditions by providing specialized and
timely medical care to patients around the world. For additional
information, visit www.corindus.com, and follow @CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of
historical or current facts are “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward-looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as “believes,” “belief,” “expects,”
“estimates,” “intends,” “anticipates” or “plans” to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements regarding or such
as:
- Corindus’ ability to bring
robotic-assisted PCI to additional markets across the globe;
and
- that robotics will provide Japan with
cutting-edge technology in interventional medicine.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled “Risk Factors” in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: our ability to expand our
technology platform and achieve the advances necessary for
telestenting and remote procedures, including in humans; our
ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional
and other more complex cardiac interventions; obtaining necessary
regulatory approvals for the use on humans and marketing of our
products in the United States and in other countries, including for
stroke and other neurovascular interventions; the rate of adoption
of our CorPath System and the rate of use of our cassettes; risks
associated with market acceptance, including pricing and
reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations;
our ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow
or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More
information is available on Corindus’ website at
http://www.corindus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190415005082/en/
Media Contact:Matter for CorindusJessica
Wolter978-518-4536corindus@matternow.comwww.matternow.com
Investor Contact:Lisa WilsonIn-Site Communications, Inc.T:
917-543-9932ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jul 2023 to Jul 2024